Table 2 Patients’ clinical and catheterization data in each group

YP (n = 60)

OP (n = 80)

p*

Male (%)

52 (86.7)

55 (68.8)

0.016

Age, years

45 (38–48)

59 (55–65)

< 0.0001

Diabetes mellitus (%)

12 (20)

31 (38.8)

0.026

Hypertension (%)

9 (15)

19 (23.8)

0.3

Smoking (%)

42 (70)

45 (56.3)

0.12

Hyperlipidemia (%)

17 (28.3)

2 (2.5)

< 0.001

Family history (%)

28 (46.7)

11 (13.8)

< 0.001

Chest pain duration, h

5 (3–7)

6 (3–9)

0.4

Ejection fraction (%)

50 (45.3–55.8)

50 (47.0–45.8)

0.4

CK-max, IU/L

2200 (1345–3234)

2168 (1464–3340)

0.6

CK-MB, μg/L

275 (201–393)

259 (200–379)

0.7

WBCs, cell/μL

8600 (5625–13175)

7580 (5805–10,200)

0.09

Door to balloon, min

35 (30–45)

35 (30–43)

0.6

Infarct related artery (%)

0.6

 LAD

37 (61.7)

44 (55)

 LCX

6 (10)

7 (8.8)

 RCA

17 (28.3)

29 (36.3)

Diseased vessels/patients (%)

2 (1–2)

2 (1–3)

0.28

Reference vessel, mm

3 (3–3.4)

3.25 (2.8–3.5)

0.15

Lesion length, mm

24.57 ± 7.91

27.56 ± 6.93

0.02

Ectatic vessel (%)

9 (15)

3 (3.8)

0.03

Thrombus grading (%)

0.28

 5

35 (58.3)

52 (65)

 4

21 (35)

20 (25)

 < 4

4 (6.7)

8 (10)

Preintervention TIMI flow (%)

0.9

 ≤ 1

55 (91.7)

74 (92.5)

 > 1

5 (8.3)

6 (7.5)

Intervention method (%)

0.02

 Aspiration

3 (5)

2 (2.5)

 POBA

7 (11.7)

1 (1.3)

 Stenting

50 (83.3)

77 (96.3)

Stent type (%)

0.8

 DES

13 (26)

18 (23.4)

 BMS

37 (74)

59 (76.6)

Stent length, mm

25 (20–33)

30 (24–38)

0.04

Stent deployment pressure, atm

14 (12–16)

14 (12–16)

0.6

Postintervention TIMI flow (%)

0.5

 3

57 (95)

75 (93.8)

 < 3

3 (5)

5 (6.2)

GPIIb/IIIa inhibitors (%)

28 (46.7)

36 (45)

0.9

ST-segment resolution (%)

45 (75)

59 (73.8)

0.9